Status:
COMPLETED
Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)
Lead Sponsor:
Sandoz
Conditions:
Rheumatoid Arthritis
Osteoarthritis
Eligibility:
All Genders
21-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2002
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00959439
Start Date
March 1 2002
End Date
May 1 2002
Last Update
March 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.